tombal
@BertrandTOMBAL
🌟Challenges in Defining Clinical CR to Systemic Therapy in MIBC🌟 @EORTC #STARBURST project 🖋️ Alexandra Masson-Lecomte @AFUrology, Guillaume Grisay, @vandamme_jvd, @Achard_Verane , @LAUrology_NL, @robert_huddart, @frasor86, @LDyrskjot, Yves Allory @institut_curie,…
🇫🇷🇧🇪Ouverture des JER du @GETUG_Unicancer avec le débat sur la prise en charge des mCRPC. ✨ @RoubaudG @BertrandTOMBAL @Helissey4 @alicebernardt
Honored to be co–first author with @ConstanceHuck on this paper challenging dogma. Next : #BRACEClinicalTrial, which I co-lead with Piet Dirix, opening soon in BE🇧🇪 thanks to #komOpTegenKanker and @EORTC . We aim to explore the role of RT in BCG-unresponsive CIS. Stay tuned!
✨ JUST OUT in EUO, New paper challenging a dogma. ⏩ MUST READ: @ConstanceHuck has done a great job to show that CIS is not always a contra-indication for Trimodal Therapy in the management of MIBC. 🙏Thanks to all co-authors for their input! sciencedirect.com/science/articl…
Why attend #RENALC25, #BLADDR25 and #PROSCA25? Hear it straight from @Achard_Verane in this quick video 👇 ➡️ Register now: tinyurl.com/mryx8kwe 💎Dive into the clinical application of new GU oncology data 👥 Learn from multidisciplinary experts 🗓️3-6 December 2025 | 📍…
ARASENS trial update (darolutamide vs placebo in combination with docetaxel + androgen deprivation therapy in metastatic hormone sensitive #ProstateCancer ) ⬆️Postprogression OS favored ARPI over taxane after placebo+docetaxel+ADT, but OS remained inferior vs darolutamide arm.…
Are we ready for ARPI alone therapy in mCSPC? Is a non-inferiority trial needed? Great lecture by @BertrandTOMBAL at #UROonco25 in Sevilla but the debate is still open... @Uroweb @EUplatinum @oncodaily @OncoAlert @urofocus @foxal72 @MRoupret
In PEACE-3 (EORTC 1333), the addition of 6 cycles of Ra223 to enzalutamide improves PSA response time and rates (≥90%), ALP reduction time (≥30%), and ALP normalization at 6 and 12 months. @EORTC @Silke_Gillessen @SoaresAndrey @GETUG_Unicancer @cancertrials_ie @sogug1
Patience and resilience are the bedrock of every academic triumph. But none of this would exist without the trust of our patients, the dedication of our nurses, and the relentless support of the EORTC HQ team. The spotlight belongs to you, not us. I love you all…@EORTC
🆕article in press: Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial @BertrandTOMBAL, @Silke_Gillessen, @EORTC tinyurl.com/bdhhv78u
Sharpen your approach to mCRPC with the latest, most revolutionary trial data, and expert guidance via @BertrandTOMBAL @PBarataMD @CaPsurvivorship on applying it to your practice. ICYMI at major meetings this year 💥 ms.spr.ly/6017Sd2rH
On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across…
Fast (< 30 min) “All-in-One” whole-body MRI for TNM staging in high-risk prostate cancer (PCa), clearly an alternative @ClinUnivStLuc @irec_ -IX ejradiology.com/article/S0720-…
Data from Peace3 presented by Fred Saad clearly suggest that early administration of bone protecting agent increase rPFS and OS in patients receiving enzalutamide +- Ra223 @EORTC @GETUG_Unicancer @sogug1 @LACOG_group @Silke_Gillessen #EAU2025
👩🏫 If you are attending the EAU Congress 2025 in Madrid, do not miss Dr Fred Saad's oral presentation on the EORTC-GUCG 1333/PEACE-3 trial today at 13:45 CET. More info available here: scientific-programme.uroweb.org/EAU25/programme #EAU25 #CancerResearch #ClinicalTrials #Oncology #EORTCgenitourinary
How to optimize outcomes in men with biochemical recurrence after local treatment with curative intent. Presentation by @BertrandTOMBAL. #EAU25 written coverage by @chavarriagaj > bit.ly/4hBGcxV @Uroweb
Very nice summary of the benefit of LHRH antagonists in patients with prostate cancer and significant LUTS @Achard_Verane #EAU2025
Proud to share that our collaborative review on Combination Therapies in Locally Advanced PC and mHSPC is now available in @EUplatinum authors.elsevier.com/sd/article/S03…. Thanks to this wonderful team, especially to @AzadOncology and Karim Fizazi. So honoured to be involved!
Join @BertrandTOMBAL & me in a fun virtual educational webinar! Link: us02web.zoom.us/webinar/regist… @mirrorsmed @mtsiatas @MichalisLiontos @AKyriazoglou @zeniasar @DanieleRaggi83 @LauraMarandino @amalsargsyan @mkmoutafi @elina_vlachou @b_szabados @umangtalking @AbhiTrip87 @OncoAlert
On the importance of optimal bone protection in patients receiving AR pathway inhibitors..@Silke_Gillessen Fred Saad and many others...@EORTC sciencedirect.com/science/articl…
A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… NOW ON FINAL SESSION of #PROSCA24 The 2024 Advanced Prostate Cancer Consensus Conference (APCCC)…
PEACE-3 trial results: Radium-223 + enzalutamide in #mCRPC. @BertrandTOMBAL @UCLouvain_be joins Oliver Sartor, MD @MayoClinic discussing the trial design, results, and implications with significant improvements in rPFS and promising interim OS data > bit.ly/4eFGHpr